当前位置: X-MOL 学术Asia Pac. J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study
Asia-Pacific Journal of Clinical Oncology ( IF 1.9 ) Pub Date : 2022-05-22 , DOI: 10.1111/ajco.13780
Shunsuke Yui 1 , Satoshi Wakita 1 , Yasunobu Nagata 1 , Yasuko Kuribayashi 1 , Toshio Asayama 1 , Yusuke Fujiwara 1 , Masahiro Sakaguchi 1 , Satoshi Yamanaka 1 , Atsushi Marumo 1 , Ikuko Omori 1 , Ryosuke Kinoshita 1 , Daishi Onai 1 , Mika Sunakawa 1 , Yuta Kaito 1 , Kazuki Inai 1 , Taichiro Tokura 1 , Atsushi Takeyoshi 1 , Shunichi Yasuda 1 , Shunsuke Honma 1 , Kazutaka Nakayama 1 , Tsuneaki Hirakawa 1 , Kunihito Arai 1 , Tomoaki Kitano 1 , Muneo Okamoto 1 , Koiti Inokuchi 1 , Hiroki Yamaguchi 1
Affiliation  

The MEAM regimen consisting of ranimustine (MCNU), etoposide (ETP), cytarabine (Ara-C), and melphalan (MEL) is widely used before auto-peripheral blood stem cell transplantation (auto-PBSCT) for malignant lymphoma in Japan. The MEAM regimen generally consists of 200–400 mg/m2 for 4 days, but we decided to increase the dosage of Ara-C from the standard to 2 g/m2 for 2 days with the aim of increasing drug transferability to the central nervous system. We evaluate the safety and therapeutic efficacy of high-dose Ara-C MEAM therapy.

中文翻译:

大剂量阿糖胞苷 MEAM 疗法与其他疗法对自身外周血干细胞移植的安全性和有效性:一项回顾性比较研究

由雷尼莫司汀 (MCNU)、依托泊苷 (ETP)、阿糖胞苷 (Ara-C) 和美法仑 (MEL) 组成的 MEAM 方案在日本恶性淋巴瘤的自体外周血干细胞移植 (auto-PBSCT) 之前被广泛使用。MEAM 方案通常由 200–400 mg/m 2组成,持续 4 天,但我们决定将 Ara-C 的剂量从标准剂量增加到 2 g/m 2,持续 2 天,目的是提高药物向中枢神经系统的转移能力神经系统。我们评估了高剂量 Ara-C MEAM 疗法的安全性和疗效。
更新日期:2022-05-22
down
wechat
bug